A recent study conducted by Novo Nordisk reveals a significant increase in prescription for glucagon-like peptide-1 (GLP-1) drugs. The research, focusing on a specific facility in Hillerod, Denmark, indicates a notable rise in the number of patients receiving these medications. The data suggests a marked increase in prescriptions compared to previous years. Novo Nordisk has stated the trend is consistent with clinical trials and is being monitored closely. The increased utilization is attributed to advancements in treatment options for type 2 diabetes and obesity.
Credits: NYT > Top Stories
